Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Approaching untargetable tumor-associated antigens with antibodies.

Dao T, Liu C, Scheinberg DA.

Oncoimmunology. 2013 Jul 1;2(7):e24678. Epub 2013 Apr 30.

2.

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA.

Sci Transl Med. 2013 Mar 13;5(176):176ra33. doi: 10.1126/scitranslmed.3005661.

3.

Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.

Ataie N, Xiang J, Cheng N, Brea EJ, Lu W, Scheinberg DA, Liu C, Ng HL.

J Mol Biol. 2016 Jan 16;428(1):194-205. doi: 10.1016/j.jmb.2015.12.002. Epub 2015 Dec 11.

4.

Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.

Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, Scheinberg DA.

Clin Cancer Res. 2014 Aug 1;20(15):4036-46. doi: 10.1158/1078-0432.CCR-13-2756. Epub 2014 May 21.

5.

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA.

Nat Biotechnol. 2015 Oct;33(10):1079-86. doi: 10.1038/nbt.3349. Epub 2015 Sep 21.

6.

Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.

Epel M, Carmi I, Soueid-Baumgarten S, Oh SK, Bera T, Pastan I, Berzofsky J, Reiter Y.

Eur J Immunol. 2008 Jun;38(6):1706-20. doi: 10.1002/eji.200737524.

7.
8.

Defining MHC class II T helper epitopes for WT1 tumor antigen.

Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, Celis E.

Cancer Immunol Immunother. 2006 Jul;55(7):850-60. Epub 2005 Oct 12.

PMID:
16220325
11.

Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.

Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O'Reilly RJ, Cheung NK.

Leukemia. 2015 Nov;29(11):2238-47. doi: 10.1038/leu.2015.125. Epub 2015 May 19.

12.
13.

[Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].

Gu WY, Cao XS, Qiu GQ, Chen ZX, Sheng LX, Xie XB, He J, Cen JN, Shen HL.

Zhonghua Yi Xue Za Zhi. 2005 Dec 28;85(49):3475-80. Chinese.

PMID:
16686063
15.
16.

Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.

Denkberg G, Reiter Y.

Autoimmun Rev. 2006 Apr;5(4):252-7. Epub 2005 Aug 8. Review.

PMID:
16697965
17.

Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.

Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K, Okamoto S, Mineno J, Kuzushima K, Shiku H, Inoue H, Yasukawa M.

PLoS One. 2013;8(2):e56820. doi: 10.1371/journal.pone.0056820. Epub 2013 Feb 18.

18.

Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.

May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55. Erratum in: Clin Cancer Res. 2007 Sep 1;13(17):5226.

19.

Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope.

Dahan R, Gebe JA, Preisinger A, James EA, Tendler M, Nepom GT, Reiter Y.

J Autoimmun. 2013 Dec;47:83-93. doi: 10.1016/j.jaut.2013.08.009. Epub 2013 Oct 3.

PMID:
24090977
20.

TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.

Verma B, Neethling FA, Caseltine S, Fabrizio G, Largo S, Duty JA, Tabaczewski P, Weidanz JA.

J Immunol. 2010 Feb 15;184(4):2156-65. doi: 10.4049/jimmunol.0902414. Epub 2010 Jan 11.

Supplemental Content

Support Center